Recently, OBiO Technology (Shanghai) Co., Ltd. (hereinafter referred to as " OBiO," stock code: 688238) and Shenzhen magicRNA Technology Co., Ltd. (hereinafter referred to as " magicRNA ") announced the signing of a strategic cooperation agreement. Both sides will carry out comprehensive cooperation in the field of LNP delivery systems, jointly promoting the clinical application of mRNA and other nucleic acid products in the fields of vaccines and cancer therapy. They aim to provide comprehensive and high-quality services to customers, enabling the industry and benefiting patients.
Win-win Cooperation: OBiO & magicRNA
magicRNA focuses on nucleic acid drug delivery and therapeutic mRNA innovative drug research and development. It possesses the largest ionizable amino lipid library with completely independent intellectual property rights in China. It has applied for more than 10 invention patents, including several PCT and European and American invention patents, of which 4 patents have been authorized. Based on combinatorial chemistry, magicRNA has developed a new ionizable amino lipid with 1,2-diester as the core framework, enabling rapid liver clearance. Engineered cell-targeted delivery platforms enable precise cell targeting to safely and efficiently deliver mRNA.
In the future, OBiO will continue to build on its own process and technological advantages, as well as various new LNP-related patented technologies proprietary by Irwin Biological, to provide customers with mRNA and other nucleic acids, from early research and development to clinical trial applications, and from clinical GMP manufacturing to commercial GMP manufacturing.
Dr.Gaofeng,Zha, founder of magicRNA Techonology,, said: “OBiO is a leading CRO and CDMO enterprise in the field of CGT in China. We are very pleased to have reached a strategic cooperation with OBiO, and also thank OBiO for its recognition of Rainbow Biology. We believe that Rainbow Biology's LNP technology can bring more possibilities and better services to OBiO and its customers. We look forward to collaborating with OBiO to advance the nucleic acid industry and further address unmet clinical needs.”
Dr.Guodong,Jia, CEO of OBiO Techonology, said: “We are very pleased to cooperate with magicRNA in the field of LNP delivery. Both parties will play their respective advantages to provide strong support for customer product development and jointly promote the application and development of mRNA and other nucleic acid drugs. As a leading company in the industry, OBiO has been committed to promoting the innovation and development of gene and cell therapy, and continuously empowering the entire industry through technological innovation and resource integration. We believe that the collaboration between the two parties will promote the development of nucleic acid drugs in clinical practice.”
About magicRNA Technology
Founded in December 2021, magicRNA is a research and development company focused on nucleic acid drug delivery and therapeutic mRNA innovation. Its corporate mission is "Deepening nucleic acid drug delivery, RNA therapy for the benefit of sufferers." HN2201, magicRNA 's first cancer therapy drug, has completed pre-clinical development and obtained ethical clinical trial approval. It is about to enter the clinical trial stage. ILB3132, which is screened from magicRNA lipid library, has completed the development of CMC, is about to complete the registration of Sino-US excipients, and has been authorized for use in several foreign countries, with a cooperation amount of hundreds of millions of yuan. At the same time, in response to industry pain points, Rainbow Bio has successfully developed an engineered cell-targeted delivery platform (Engineered Cell Targeted LNPs, EnC-LNPs). The platform enables engineered and precise cell-targeted delivery and has comparable physicochemical properties and stability to traditional LNPs. They have achieved nearly 100% efficient and selective delivery of immune cells in vitro and in vivo and have completed a patented layout, promising to deliver targeted cells to any purpose in the future.
About OBiO Technology
The state-of-the-art 77,000-square-meter Facility for Global Supply exemplifies our commitment to meeting worldwide demand. We provide comprehensive CDMO services encompassing process development, analytical methods, IND-enabling CMC (Chemistry, Manufacturing, and Controls), as well as clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products. Our expertise extends to offering holistic solutions tailored to support the industrialization and commercialization of various products at the Pre-IND stage and beyond.
